放疗同步联合化疗对照单纯化疗治疗局部晚期非小细胞肺癌的临床研究

《放疗同步联合化疗对照单纯化疗治疗局部晚期非小细胞肺癌的临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、放疗同步联合化疗对照单纯化疗治疗局部晚期非小细胞肺癌的临床研究　　【摘要】目的研究观察放疗同步联合化疗对照单纯化疗治疗局部晚期非小细胞肺癌疗效。方法CT、病理学证实的局部晚期非小细胞肺癌62例，随机分成同步放化疗组和单纯化疗组。放疗均采用三维适形放疗，两组化疗方案均采用紫杉醇联合卡铂，共二个周期。治疗结束后比较两组疗效及不良反应。结果同步放化疗组和单纯化疗组的有效率分别为64.5%和38.7%（P=0.042），一年生存率分别为58.1%和29.0%（P=0.021），两组间疗效与一年生存率均存在显著统计学差异。两组

2、不良反应主要表现为白细胞减少、血小板减少、肝功能异常、心脏毒性、恶性呕吐等，不良反应均无统计学差异（P>0.05）。结论同步化放疗能明显提高治疗局部晚期非小细胞肺癌有效率和近期生存率，且与单纯化疗相比并不增加不良反应。　　【关键词】局部晚期非小细胞肺癌;同步放化疗;化学治疗Clinicalstudyofradiotherapycombinedwithconcurrentchemotherapycomparedwithsimplechemotherapyforlocallyadvancednon-smallcel

3、llungcancerXie-Jun1，LiuDe-gan2，XuWen-jing2，ZhaiChen-tong2（1DepartmentofOncology，XinghuaThirdPeople'sHospital，JiangsuXinghua225700，china;2DepartmentofOncology，XinghuaPeople'sHospital，JiangsuXinghua225700，china）　　[Abstract]ObjectiveTostudytheeffectofconcurrentche

4、moradiotherapycomparedwithsimpleradiotherapyforlocallyadvancednon-mallcelllungcancer.Methods62casesofnon-smallcelllungcancerconfirmedbyCTandpathologyw-ererandomlydividedintoconcurrentchemoradiotherapygroupandsimplechemot-herapygroup.Radiotherapyweretreatedbythr

5、ee-dimensionalconformalradioth-erapy，Thetwogroupsweretreatedfortwocycleswithpaclitaxelandcarbopla-tin.ResultTheeffectiverateofconcurrentchemoradiotherapygroupandsimplechemotherapygroupwererespectively64.5%and38.7%（P=0.042）.One-yearsurvi-valrateswererespectively

6、58.1%and29%（P=0.021）.Theeffectiverateandone-yearsurvivalrateofthetwogroupswerestatisticallysignificantdifference.Adversereactionsofthetwogroupsmainlyforwhitebloodcellreduced、throm-bocytopenia、liverdysfunction、cardiactoxicity、nauseaandvomitingetal.Th-erewerenosi

7、gnificantdifferencesinadversereactions（P>0.05）.ConclusionsConcurrentchemoradiotherapyforlocallyadvancednon-smallcelllungcancerc-ansignificantlyimprovethecurativeeffectandone-yearsurvivalrate，butd-　　on’tincreasetheadverserea-ctionscomparedwithsimplechemothera

8、py.　　[Keywords]Locallyadvancednon-smallcelllungcancer;Concurrentchemoradiotherapy;Chemotherapy　　肺癌在肿瘤发病中居首位[1]，其中非小细胞肺癌（NSCLC）占80%以上。临床上I、Ⅱ期NSCLC手术治疗的5年生存率为约为40%，遗憾的是可手术的仅占全